She also noted that there are no data to address the use of palivizumab in children over 2 years of age or in those with cerebral palsy, neurologic disease, metabolic disease, or immunodeficiency.
Dr. Ackerman disclosed that she is on the speakers' bureau for GlaxoSmithKline Inc., maker of Zovirax (generic name acyclovir) and for AstraZeneca.